Prospective Phase I/II Trial of Carbon Ion Radiotherapy for Locally Advanced Non-small-cell Lung Cancer (NSCLC) Abstract title: CIRT for Locally Advanced.

Slides:

Advertisements

Similar presentations

Pulmonary Stereotactic Ablative Radiotherapy:

Advertisements

I I. B.- T R E A T M E N T P L A N: DOCETAXEL 75 mg/m2 40 mg/m2 THORACIC RT (66 Gys: 180 cGy/d) CISPLATIN 40 mg/m2 Days E V A L U A.

CARBON ION THERAPY FOR SACRAL CHORDOMAS

Neoadjuvant Chemotherapy in Malignant Peripheral Nerve Sheath Tumors Elizabeth Shurell, M.D., M.Phil. UCLA General Surgery Resident Research Fellow, Division.

Stereotactic Body Radiation Therapy (SBRT): The optimal indication for operable tumors in inoperable patients D.Katsochi 1, S.Kosmidis 1, A.Fotopoulou.

Neoadjuvant Chemotherapy in Ovarian Cancer Key issues in trial design.

Dr. LP Si Tseung Kwan O Hospital. Introduction CA stomach is the 4 th most commonly diagnosed malignancy worldwide 2 nd most common cause of cancer-related.

Neoadjuvant Adjuvant Curative Palliative Neoadjuvant Radiation therapy the results of a phase III study from Beijing demonstrated a survival benefit.

Capecitabine versus 5-fluorouracil-based (neo-)adjuvant chemo-radiotherapy for locally advanced rectal cancer: Long term results.

Abstract No A Phase I/II Study of the Angiogenesis Inhibitor Sorafenib in Cervical Cancer Patients Treated with Radiotherapy Naz Chaudary A. Fyles,

INTRODUCTION  The majority of clinical trials addressing outcomes in limited- stage small cell lung cancer (LS-SCLC) following definitive chemoradiotherapy.

Experience and Outcomes with Hypofractionated Concurrent Chemoradiation for Stage III NSCLC at NCCC Gregory Webb Medical Student.

A phase I study on the combination of neoadjuvant radiotherapy plus pazopanib in patients with locally advanced soft tissue sarcoma of the extremities.

1 Non–Small-Cell Lung Cancer Diagnosis and Staging EvaluationPurpose Physical examinationIdentify signs Chest x-rayDetermine position, size, number of.

Sequential vs. concurrent chemoradiotherapy for locally advanced non-small cell carcinoma.

Clinical Outcomes and Patterns of Failure in Pineoblastoma: A 30-year Single Institution Experience Benjamin Farnia, B.A. ASTRO Poster Discussion September.

Proton Therapy for Chondrosarcomas of the Skull Base and Cervical Spine: Long-term Experience at Loma Linda University Medical Center D. Y. Kim 2, R. W.

Global Investigation of therapeutic DEcisions in hepatocellular carcinoma and Of its treatment with sorafeNib (GIDEON) study.

Clinico-Dosimetric Correlation for Acute and Chronic Gastrointestinal Toxicity in Patients of Locally Advanced Carcinoma Cervix Treated With Conventional.

Definitive chemo-radiotherapy for esophageal cancer; failure pattern and salvage treatments Ryuta Koike, Y. Nishimura, K. Nakamatsu, S. Kanamori, M. Okubo,

Postoperative Radiotherapy for Patients with Stage II or III Nonsmall Cell Lung Cancer treated with Sublobar Resections: A SEER Registry Analysis Scott.

PHASE I TRIAL OF CONCURRENT CHEMORADIOTHERAPY USING DOXIFLURIDINE AND PACLITAXEL IN ADVANCED BREAST CANCER H.Hirowatari 1, K. Karasawa 1,2,

(4) Radiation Therapy Oncology Group (RTOG)

Radiation Therapy in the Management of Cervical Carcinoma Patrick S Swift, MD Medical Director, Radiation Oncology Alta Bates Comprehensive Cancer Center.

Recent Advances in Head and Neck Cancer Robert I. Haddad, M.D., and Dong M. Shin, M.D. The NEW ENGLAND JOURNAL of MEDICINE N Engl J Med 2008;359:

The Use of Trastuzumab in the Elderly in the Adjuvant Setting and After Disease Progression in Patients with HER2-Positive Advanced Breast Cancer Dall.

Comparison of SIB-IMRT and Conventional Accelerated Hyper-fractionated IMRT With Concurrent Cisplatin and Etoposide for Limited Disease SCLC Baosheng Li.

Simon K. Cheng 1, Kevin Stephenson 2, Lynn Shi 2, Kunal Chaudhary 1, Anshu Jain 1, David P. Horowitz 1, Sherry X. Yan 2, Tony Wang 1, Clifford Chao 1,

Adjuvant High-Dose-Rate Brachytherapy Alone for Stage I/II Endometrial Adenocarcinoma using a 4-Gray versus 6-Gray Fractionation Scheme Marie Lynn Racine,

Title: Stereotactic Ablative Radiotherapy (SABR) can be Safe and Effective for Treatment of Central and Ultra-Central Lung Tumors. Author: Aadel Chaudhuri,

Evidence for a Survival Benefit Conferred by Adjuvant Radiotherapy in a Cohort of 608 Women with Early-stage Endometrial Cancer O. Kenneth Macdonald 1,

Stereotactic Ablative Body Radiotherapy for Non small cell lung cancer

Conflict of Interest Declaration: Nothing to Disclose Presenter: Sophie Lamoureux Title of Presentation: A Comparison of Stereotactic Body Radiotherapy.

. Background Paclitaxel and Irinotecan in Platinum Refractory or Resistant Small Cell Lung Cancer: a Galician Lung Cancer.

High Dose Rate Brachytherapy Boost for Prostate Cancer: Comparison of Two Different Fractionation Schemes Tania Kaprealian 1, Vivian Weinberg 3, Joycelyn.

Outcomes of Stereotactic Ablative Radiotherapy (SABR) for a Second Primary Lung Cancer (SPLC): Evidence in Support of Routine CT Surveillance C. J.A. Haasbeek,

Approaching early stage disease

Effect of multiple-phase regional intra-arterial infusion chemotherapy on patients with resectable pancreatic head adenocarcinoma JIN Chen, YAO Lie, LONG.

S1207: Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients.

Increased Local Control of Lung and Liver Tumors Associated with Dose-Escalated Stereotactic Body Radiation Therapy (SBRT) Supports a Dose-Response Relationship.

Neoadjuvant FOLFOX with Bevacizumab but without Pelvic Radiation for Locally Advanced Rectal Cancer Schrag D et al. Proc ASCO 2010;Abstract 3511.

Erlotinib plus Gemcitabine Compared with Gemcitabine Alone in Patients with Advanced Pancreatic Cancer: A Phase III Trial of the National Cancer Institute.

What Factors Predict Outcome At Relapse After Previous Esophagectomy And Adjuvant Therapy in High-Risk Esophageal Cancer? Edward Yu 1, Patricia Tai 5,

Adjuvant and Neoadjuvant Therapy in Non- Small Cell Lung Cancer Seminars in Oncology 2oo5;32 (suppl 2):S9-S15 Kyung Hee Medical Center Department of Thoracic.

2 years versus 1 year of adjuvant trastuzumab for HER2-positive breast cancer (HERA): an open-label, randomised controlled trial Aron Goldhirsch, Richard.

OPTIMAL STRATEGY FOR PROPHYLACTIC CRANIAL IRRADIATION IN LIMITED STAGE SMALL CELL LUNG CANCER Patricia Tai 1, Avi Assouline 2,3, Kurian Joseph 4, Edward.

핵의학과 PK 18 조 68 번 주리히 Case presentation 2 Disease review 3 Journal review.

Neoadjuvant chemotherapy in the treatment of NSCLC Department of Thoracic Oncology, University Hospital Ghent, Belgium Current Opinion in Oncology 2007,

NEW RADIOTHERAPY AND CHEMORADIOTHERAPY APPROACHES FOR NON–SMALL-CELL LUNG CANCER Joseph K. Salama and Everett E. Vokes J Clin Oncol 31: R4 신재령.

Clinical outcomes and prognostic factors of patients with advanced hepatocellular carcinoma treated with sorafenib as first-line therapy : A Korean multicenter.

Emily Tanzler, MD Waseet Vance, MD

Signs, Symptoms, Interventions ACKNOWLEDGEMENTS AND CONTACTS

Results of Definitive Radiotherapy in Anal Canal Carcinoma

Stage I Non Small Cell Lung Cancer (NSCLC): single centre comparison of outcome by treatment with surgery, conventional radiotherapy and stereotactic ablative.

1 Maidstone and Tunbridge Wells NHS Trust (Kent Oncology Centre)

ADSCaN A Randomised Phase II study of Accelerated, Dose escalated, Sequential Chemo-radiotherapy in Non-Small Cell Lung Cancer Rationale: Lung cancer.

Compassionate People World Class Care

Treatment With Continuous, Hyperfractionated, Accelerated Radiotherapy (CHART) For Non-Small Cell Lung Cancer (NSCLC): The Weston Park Hospital Experience.

Concurrent chemotherapy and hyperthermia in patients with recurrent cervical cancer after chemoradiation: outcome and survival S.T. Heijkoop1,2; H.C. van.

L. A. den Otter. , R. M. Anakotta. , M. Dieters. , C. T. Muijs. , S

New developments in oncological treatment for Stage 3 NSCLC

Locally Advanced NSCLC Implementing Innovation

Ansell SM et al. Proc ASH 2012;Abstract 798.

Neoadjuvant Adjuvant Curative Palliative

A Dose Escalation Clinical Trial of Single-Fraction Carbon Ion Radiotherapy for Peripheral Stage I Non–Small Cell Lung Cancer Naoyoshi Yamamoto, MD,

Rarer Bone Tumors Thomas F. DeLaney, M.D. Co-Director: Sarcoma Program

Treatment of Stage III Non-small Cell Lung Cancer

Proton Beam Therapy for Liver Cancer is Well Tolerated: Outcomes from the Proton Collaborative Group REG Trial Michael Chuong, M.D.1,2, Smith Apisarnthanarx,

Results: Purpose/Objectives: Methods: Conclusions:

Glucose levels must be monitored in patients receiving steroids for immunotherapy-related toxicity Title: Subtitle Risk Assessment of Hyperglycaemia Induced.

Presentation transcript:

Prospective Phase I/II Trial of Carbon Ion Radiotherapy for Locally Advanced Non-small-cell Lung Cancer (NSCLC) Abstract title: CIRT for Locally Advanced NSCLC W. Takahashi* 1,2, N. Yamamoto 2, M. Nakajima 2, A. Sakumi 1, H. Yamashita 1, K. Nakagawa 1, H. Tsuji 2, T. Kamada 2 1.Research Center of Charged Particle Therapy, National Institute of Radiological Sciences 2.Department of Radiology, The University of Tokyo Hospital Session title: Lung 2 - Locally Advanced Disease and Imaging Date/Time: :45 Location: Room D-2 Monitor number: 8

CIRT for locally advanced NSCLC Background/Purpose Although concurrent chemoradiotherapy (CCRT) has become the standard approach for unresectable LA-NSCLC, most patients are not candidates for this treatment due to comorbidities. To assess outcomes and the toxicity of CIRT for medically inoperable/unresectable LA-NSCLC, a single-institution Phase I/II trial was conducted. M&M Clinical stage IIA to IIIB (UICC 6 th ed) LA-NSCLC patients were enrolled. Phase I (dose escalation): 68, 72, 76 GyE (16 fractions/4 weeks) ⇨ Phase II: the recommended dose based on the Phase I study Respiratory-gated CIRT was delivered using 3 or 4 coplanar beam angles.

CIRT for locally advanced NSCLC Results Of the 36 patients treated in Phase I, two grade 3 adverse events (radiation pneumonitis and tracheoesophageal fistula) were observed in the 76 GyE group. Accordingly, for Phase II, the next consecutive 26 patients were treated with 72 GyE, with no grade 3 to 5 toxicities resulting. For the entire cohort, the 3-year overall survival (OS), local control rate (LCR), disease-free survival (DFS), and cause-specific survival (CSS) were 43.0%, 93.1%, 28.9%, and 66.6%, respectively. The most frequent pattern of initial disease progression was distant metastases alone (18 patients), followed by regional lymph node and distant metastases (5 patients). We observed 3 local recurrences. As expected, N2 metastases were found to be significantly associated with poor prognosis (23% 3-year overall survival, P =.03).

Take home points The management of inoperable LA-NSCLC patients who are not candidates for CCRT remains one of the most challenging issues in oncology. As a new management option for such LA-NSCLC patients, our standard CIRT regimen (72GyE/16fr) has the potential to improve survival. We were able to achieve, with manageable toxicity, a 3y-LCR and 3y- OS of 93.1% and 43.0%, respectively.